|Tumour heterogeneity in the clinic|
PL Bedard, AR Hansen, MJ Ratain, LL Siu
Nature 501 (7467), 355, 2013
|Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas|
SH Huang, W Xu, J Waldron, L Siu, X Shen, L Tong, J Ringash, A Bayley, ...
J Clin Oncol 33 (8), 836-845, 2015
|Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review|
L Khoja, D Day, T Wei-Wu Chen, LL Siu, AR Hansen
Annals of Oncology 28 (10), 2377-2385, 2017
|A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors|
TW Chen, AR Razak, PL Bedard, LL Siu, AR Hansen
Annals of Oncology 26 (9), 1824-1829, 2015
|Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial|
TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ...
Genome medicine 8 (1), 109, 2016
|Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study|
C Hsu, SH Lee, S Ejadi, C Even, RB Cohen, C Le Tourneau, JM Mehnert, ...
Journal of Clinical Oncology 35 (36), 4050-4056, 2017
|Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking|
M Poudineh, PM Aldridge, S Ahmed, BJ Green, L Kermanshah, V Nguyen, ...
Nature nanotechnology 12 (3), 274, 2017
|A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer|
MA Sukhai, KJ Craddock, M Thomas, AR Hansen, T Zhang, L Siu, ...
Genetics in Medicine 18 (2), 128, 2016
|PD-L1 testing in cancer: challenges in companion diagnostic development|
AR Hansen, LL Siu
JAMA oncology 2 (1), 15-16, 2016
|Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study|
AR Hansen, C Massard, PA Ott, NB Haas, JS Lopez, S Ejadi, ...
Annals of Oncology 29 (8), 1807-1813, 2018
|Immune-related adverse events associated with immune checkpoint inhibitors|
D Day, AR Hansen
BioDrugs 30 (6), 571-584, 2016
|Pembrolizumab for patients with advanced prostate adenocarcinoma: preliminary results from the KEYNOTE-028 study|
A Hansen, C Massard, PA Ott, N Haas, J Lopez, S Ejadi, J Wallmark, ...
Annals of Oncology 27 (suppl_6), 725PD, 2016
|Early phase clinical trials to identify optimal dosing and safety|
N Cook, AR Hansen, LL Siu, ARA Razak
Molecular oncology 9 (5), 997-1007, 2015
|A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.|
JR Infante, AR Hansen, MJ Pishvaian, LQM Chow, GA McArthur, ...
Journal of Clinical Oncology 34 (15_suppl), 101-101, 2016
|Epidermal growth factor receptor targeting in head and neck cancer: have we been just skimming the surface|
AR Hansen, LL Siu
J Clin Oncol 31 (11), 1381-1383, 2013
|988pd clinical activity and safety of Medi4736, an anti-Pd-L1 antibody, in patients with head and neck cancer|
M Fury, SI Ou, A Balmanoukian, A Hansen, E Massarelli, A Blake-Haskins, ...
Annals of Oncology 25 (suppl_4), iv341-iv341, 2014
|Phase 1 trial design: is 3+ 3 the best?|
AR Hansen, DM Graham, GR Pond, LL Siu
Cancer Control 21 (3), 200-208, 2014
|A comprehensive review of immunotherapies in prostate cancer|
MC Maia, AR Hansen
Critical reviews in oncology/hematology 113, 292-303, 2017
|Conditional risk of relapse in surveillance for clinical stage I testicular cancer|
M Nayan, MAS Jewett, A Hosni, L Anson-Cartwright, PL Bedard, M Moore, ...
European urology 71 (1), 120-127, 2017
|Immuno-oncology trial endpoints: capturing clinically meaningful activity|
V Anagnostou, M Yarchoan, AR Hansen, H Wang, F Verde, E Sharon, ...
Clinical Cancer Research 23 (17), 4959-4969, 2017